Home › Squamous Cell Carcinoma ng Ulo at Leeg › California › Irvine
Pag-aaral pangklinika para sa Squamous Cell Carcinoma ng Ulo at Leeg sa Irvine, CA
Isang pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Irvine. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Nagre-recruitPhase 1
- City of Hope at Irvine Lennar, Irvine
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Nagre-recruitPhase 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Nagre-recruitPhase 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Nagre-recruitPhase 1/2
- City of Hope, Irvine, Irvine
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Nagre-recruitPhase 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Nagre-recruitPhase 1
- City of Hope at Irvine Lennar, Irvine
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Nagre-recruitPhase 1
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278432, Irvine
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Nagre-recruitPhase 1
- Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Nagre-recruitPhase 1
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589, Irvine
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Nagre-recruitPhase 1/2
- University of California, Irvine, Irvine
Pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg sa ibang lungsod
- Houston, TX47 pag-aaral
- Los Angeles, CA42 pag-aaral
- Boston, MA40 pag-aaral
- New York City, NY39 pag-aaral
- Nashville, TN39 pag-aaral
- St. Louis, MO28 pag-aaral
- Arlington, VA26 pag-aaral
- Philadelphia, PA26 pag-aaral
- Chicago, IL26 pag-aaral
- Atlanta, GA24 pag-aaral
- San Antonio, TX22 pag-aaral
- New Haven, CT22 pag-aaral
Iba pang pag-aaral sa Irvine
- Non-Small Cell Lung Cancer25 pag-aaral
- Kanser sa Suso23 pag-aaral
- Kanser (lahat ng uri)17 pag-aaral
- Metastatic Cancer16 pag-aaral
- Kanser sa Baga15 pag-aaral
- Multiple Myeloma14 pag-aaral
- Kanser sa Prostate14 pag-aaral
- Kanser sa Ovary12 pag-aaral
- Kanser sa Pantog11 pag-aaral
- Sakit ni Alzheimer11 pag-aaral
- Colorectal Cancer10 pag-aaral
- Kanser sa Pancreas10 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.